Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
Top Page
Valiant Laboratories Ltd.
(VALIANTLAB)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹77.00
▲(4.76% Upside)
Action:ReiteratedDate:04/24/26
The score is held down primarily by weak financial performance (declining profitability and significant cash flow issues). Technical indicators are constructive and provide the main support to the score, while valuation remains constrained by loss-making results (negative P/E) and no dividend yield data.
Positive Factors
B2B API manufacturing
Valiant operates a durable B2B API manufacturing model supplying formulators and finished-dose makers. Such supplier relationships are typically recurring, driven by regulatory approvals and quality compliance, creating sticky demand and predictable revenue streams over months to years.
Negative Factors
Negative free cash flow
Persistent negative free cash flow and poor conversion of earnings to cash reduce the firm's ability to fund working capital, capex, and debt service internally. Over months, this increases reliance on external financing or asset sales, constraining strategic flexibility and investment.
Read all positive and negative factors
Positive Factors
Negative Factors
B2B API manufacturing
Valiant operates a durable B2B API manufacturing model supplying formulators and finished-dose makers. Such supplier relationships are typically recurring, driven by regulatory approvals and quality compliance, creating sticky demand and predictable revenue streams over months to years.
Read all positive factors
Valiant Laboratories Ltd. (VALIANTLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹4.28B
Dividend YieldN/A
Average Volume (3M)1.58K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth91.43%
EPS Growth18.68%
CountryIN
Employees77
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.30
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.46
Price to Sales (P/S)2.47
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Valiant Laboratories Ltd. Business Overview & Revenue Model
Company Description
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States ph...
How the Company Makes Money
Valiant Laboratories Ltd. primarily makes money by manufacturing and selling APIs (and related pharmaceutical inputs) to business customers such as pharmaceutical formulators and finished-dosage manufacturers. Revenue is generated from product sal...
Valiant Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.84B | 1.39B | 1.82B | 3.34B | 2.92B | 1.82B |
| Gross Profit | 267.32M | 222.17M | 115.76M | 565.90M | 523.21M | 583.90M |
| EBITDA | 92.87M | 7.55M | -85.98M | 399.53M | 442.67M | 514.14M |
| Net Income | 50.70M | -22.01M | 3.20M | 289.98M | 274.96M | 305.93M |
Balance Sheet | ||||||
| Total Assets | 4.25B | 4.01B | 3.43B | 2.13B | 1.82B | 1.06B |
| Cash, Cash Equivalents and Short-Term Investments | 629.06M | 759.91M | 1.44B | 353.61M | 205.33M | 189.37M |
| Total Debt | 537.68M | 1.22B | 767.08M | 602.17M | 611.26M | 6.04M |
| Total Liabilities | 1.07B | 1.67B | 1.06B | 1.12B | 1.10B | 177.32M |
| Stockholders Equity | 3.17B | 2.34B | 2.37B | 1.00B | 714.60M | 885.82M |
Cash Flow | ||||||
| Free Cash Flow | -1.39B | -1.13B | -439.85M | 183.70M | -46.25M | 74.40M |
| Operating Cash Flow | -57.24M | 13.13M | 18.85M | 560.51M | 22.51M | 91.09M |
| Investing Cash Flow | -604.96M | -527.68M | -1.44B | -551.68M | -122.38M | -166.69M |
| Financing Cash Flow | 576.22M | 446.53M | 1.52B | -9.34M | 61.81M | 114.30M |
Valiant Laboratories Ltd. Technical Analysis
Positive
73.50
Price Trends
58.25
Positive
62.80
Positive
76.37
Negative
Market Momentum
1.95
Negative
67.71
Neutral
85.70
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VALIANTLAB, the sentiment is Positive. The current price of 73.5 is above the 20-day moving average (MA) of 58.01, above the 50-day MA of 58.25, and below the 200-day MA of 76.37, indicating a neutral trend. The MACD of 1.95 indicates Negative momentum. The RSI at 67.71 is Neutral, neither overbought nor oversold. The STOCH value of 85.70 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:VALIANTLAB.
Valiant Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹1.37B | 21.48 | ― | ― | 18.92% | -53.80% | |
56 Neutral | ₹548.92M | 172.45 | ― | ― | -27.51% | 356.89% | |
52 Neutral | ₹4.28B | -13.45 | ― | ― | 91.43% | 18.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹398.81M | -4.63 | ― | ― | -48.93% | -180.45% | |
45 Neutral | ₹1.30B | -11.90 | ― | ― | -53.19% | 6.75% | |
39 Underperform | ₹561.33M | -2.21 | ― | ― | -35.33% | -65.64% |
* Healthcare Sector Average
IN:VALIANTLAB
Valiant Laboratories Ltd.
78.85
-13.83
-14.92%
IN:ALPA
Alpa Laboratories Limited
65.01
-38.04
-36.91%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
33.73
-10.54
-23.81%
IN:KREBSBIO
Krebs Biochemicals & Industries Ltd.
60.12
-18.53
-23.56%
IN:LASA
Lasa Supergenerics Ltd.
7.96
-9.06
-53.23%
IN:VIVIMEDLAB
Vivimed Labs Limited
6.77
1.87
38.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.